

COVID-19 IMPACT

This report has been affected by the COVID-19 pandemic. All forecasts and analysis have been revised to reflect the current view including the effect of the pandemic and associated recession.

RESEARCH REPORT



**MOLECULAR DIAGNOSTICS FOR CANCER.
MARKETS, STRATEGIES AND TRENDS. FORECASTS BY CANCER
TYPE, INCLUDING COMPANION DX AND BY COUNTRY. WITH
EXECUTIVE AND CONSULTANT GUIDES AND COVID PANDEMIC
RECESSION FORECAST REVISIONS.
2021 TO 2025**



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

i. Molecular Dx Oncology Market - Strategic Situation Analysis with Impact of the COVID Pandemic	16
ii. Guide for Executives, Marketing, Sales and Business Development Staff	19
iii. Guide for Management Consultants and Investment Advisors	20
1. Introduction and Market Definition	21
1.1 What is Molecular Diagnostics.....	22
1.2 The Diagnostics Revolution.....	22
1.3 Market Definition	24
1.3.1 Revenue Market Size	24
1.4 Methodology	25
1.4.1 Authors	25
1.4.2 Sources	25
1.5 U.S. Medical Market and laboratory Testing - Perspective	26
1.5.1 U.S. Medicare Expenditures for Laboratory Testing	26
2. Market Overview	28
2.1 Market Participants	29
2.1.1 Academic Research Lab	30
2.1.2 Diagnostic Test Developer.....	30
2.1.3 Genomic Instrumentation Supplier	30
2.1.4 Pharmaceutical/Reagent Supplier.....	31
2.1.5 Independent Testing Lab.....	31
2.1.6 Public National/regional lab	31
2.1.7 Hospital lab	32
2.1.8 Physician Lab	32
2.1.9 Audit Body	32

2.1.10 Certification Body.....	33
2.2 Market Segments.....	34
2.2.1 Traditional Market Segmentation.....	34
2.2.2 Laboratory Focus and Segmentation.....	35
2.3 Industry Structure	37
2.3.1 Hospital Testing Share	37
2.3.2 Economies of Scale.....	37
2.3.3 Physician Office Lab's.....	39
2.3.4 Physician's and POCT	39
3. Market Trends.....	40
3.1 Factors Driving Growth.....	41
3.1.1 New Diagnostics Create New Markets.....	41
3.1.2 New Roles for Diagnostics.....	42
3.1.3 Longevity and Outcomes.....	42
3.1.3 Expanding the Pharmaceutical Toolbox.....	43
3.1.4 Regulatory Retreat	43
3.2 Factors Limiting Growth.....	44
3.2.1 Falling Prices.....	44
3.2.2 Lower Costs.....	45
3.2.3 COVID Pandemic.....	45
3.2.4 Wellness has a Downside	45
3.3 Instrumentation and Automation.....	46
3.3.1 Instruments Key to Market Share	46
3.3.2 Bioinformatics Plays a Role	46
3.4 Diagnostic Technology Development.....	47
3.4.1 Next Generation Sequencing	48
3.4.2 Shifting Role of Diagnostics.....	50
3.4.3 Multiplexing and Foundation One	51

3.4.4 Pharmacogenomics Technology	51
3.4.5 Whole Genome Sequencing	52
3.4.6 Gene Editing and Gene Therapy.....	52
4. Molecular Diagnostics Recent Developments.....	54
Recent Developments – Importance and How to Use This Section.....	55
Importance of These Developments	55
How to Use This Section	55
Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform	55
Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test.....	56
Metastatic Cancer Markers Identified in Clinical WGS Study.....	57
Stitch Bio Bets on CRISPR Tech.....	59
Bayer, LifeLabs Launch Free NTRK Genetic Testing Program.....	63
Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx.....	64
Progress, Challenges in Liquid Biopsy Reimbursement	65
Israeli Startup Curesponse Raises \$6M	68
Coronavirus Pandemic Bites into European Cancer Research.....	69
Veracyte's Prosigna IDs Patients Likely to Benefit from Aggressive Chemotherapy	71
Combining CRISPR and Nanopore Sequencing	72
Liquid Biopsy Detects Cancer Early via Cell Clusters.....	74
Roche, Illumina unveil 15-year cancer diagnostic tie-up	77
Saga, Servier Sign Liquid Biopsy Services Deal	78
Home urine test could revolutionize diagnosis of prostate cancer.....	78
Cancer Gene Tests Cost-Effective for Breast Cancer Patients.....	79
Personal Genome Diagnostics Gets CE Mark for Elio Tissue Assay	81
OncoCyte to Buy Cancer Testing Company Razor Genomics	81
Blood Test May Eliminate Need for Exploratory Surgery	83
NGS Cancer Panel Receives New York State Conditional Approval	84
Biocartis Inks Cancer CDx Deal With Bristol-Myers Squibb	84

5. Profiles of Key MDx Companies	86
10x Genomics, Inc.....	87
Abbott Diagnostics.....	88
AccuraGen Inc.....	89
Adaptive Biotechnologies	90
Aethlon Medical.....	91
Agena Bioscience, Inc.....	92
Agilent	94
Anchor Dx	96
ANGLE plc	97
ApoCell, Inc.	98
ArcherDx, Inc.	99
ARUP Laboratories.....	100
Asuragen.....	102
AVIVA Biosciences	103
Baylor Miraca Genetics Laboratories	104
Beckman Coulter, Inc.	105
BGI Genomics Co. Ltd	107
Bioarray Genetics.....	109
Biocartis	110
Biocept, Inc.....	111
Biodesix Inc.	112
BioFluidica	113
BioGenex.....	114
Biolidics Ltd.....	116
bioMérieux Diagnostics.....	117
Bioneer Corporation.....	118
Bio-Rad Laboratories, Inc.....	120

Bio-Reference Laboratories	122
Bio-Techne	123
Bioview	124
Bolidics.....	125
Boreal Genomics	126
Bristol-Myers Squibb	127
Cancer Genetics.....	128
Caris Molecular Diagnostics	129
CellMax Life.....	130
Cepheid (now Danaher)	131
Charles River Laboratories	132
Chronix Biomedical	133
Circulogene	134
Clinical Genomics	135
Cynvenio	136
Cytolumina Technologies Corp.	137
CytoTrack.....	138
Datar Cancer Genetics Limited	139
Diagnologix LLC.....	140
Diasorin S.p.A.	141
Enzo Life Sciences, Inc.	142
Epic Sciences.....	143
Epigenomics AG.....	144
Eurofins Scientific	145
Exosome Diagnostics.....	147
Exosome Sciences	148
Fabric Genomics	149
Fluidigm Corp	150

Fluxion Biosciences	151
Foundation Medicine.....	152
Freenome	153
FUJIFILM Wako Diagnostics	154
GeneFirst Ltd.	155
Genetron Health (Beijing) Co., Ltd.....	156
Genomic Health	157
GenomOncology	158
GILUPI Nanomedizin	159
Grail, Inc.	160
Guardant Health	161
HaliuDx	162
HansaBiomed	163
HeiScreen	164
Helomics.....	165
Horizon Discovery	166
HTG Molecular Diagnostics.....	167
iCellate	168
Illumina	169
Incell Dx.....	170
Inivata.....	171
Integrated Diagnostics.....	172
Invivogen	173
Invivoscribe	174
Janssen Diagnostics	175
MDNA Life SCIENCES, Inc.....	176
MDx Health	177
Menarini Silicon Biosystems	178

Millipore Sigma.....	179
Miltenyi Biotec.....	180
MIODx.....	181
miR Scientific.....	182
Molecular MD.....	183
MyCartis.....	184
Myriad Genetics/Myriad RBM.....	185
NantHealth, Inc.	186
Natera.....	187
NeoGenomics.....	188
New Oncology.....	189
Novogene Bioinformatics Technology Co., Ltd.	190
Oncocyte.....	192
OncoDNA.....	193
Ortho Clinical Diagnostics.....	194
Oxford Nanopore Technologies.....	195
Panagene.....	197
Perkin Elmer.....	198
Personal Genome Diagnostics.....	199
Personalis.....	200
Precipio.....	201
PrecisionMed.....	202
Promega.....	203
Qiagen Gmbh.....	205
Rarecells SAS.....	207
RareCyte.....	208
Roche Molecular Diagnostics.....	210
ScreeCell.....	212

Sense Biodetection.....	213
Serametrix	214
Siemens Healthineers	215
Silicon Biosystems.....	217
simfo GmbH	218
Singulomics	220
SkylineDx.....	221
Stratos Genomics	222
Sysmex Inostics.....	223
Tempus Labs, Inc.	224
Thermo Fisher Scientific Inc.....	225
Thrive Earlier Detection	227
Todos Medical	228
Trovagene	229
Volition.....	230
Vortex Biosciences	231
6. The Global Market for MDx Cancer	232
6.1 MDx Cancer – Global Market Overview by Country	233
6.1.1 Table – Global Market by Country.....	233
6.1.2 Chart - Global Market by Country	234
7. Global MDx Cancer Markets – By Type of Cancer.....	235
7.1 Global Market by Cancer Type - Overview	236
7.1.1 Table – Global Market by Cancer Type	236
7.1.2 Chart – Global Market by Cancer Type – Base/Final Comparison	237
7.1.3 Chart – Global Market by Cancer Type – Base Year	238
7.1.4 Chart – Global Market by Cancer Type –Final Year.....	239
7.1.5 Chart – Global Market by Cancer Type – Share by Year	240
7.1.6 Chart – Global Market by Cancer Type – Segment Growth	241

7.2 MDx Breast Cancer	242
7.2.1 Table Breast Cancer Testing – by Country	242
7.2.2 Chart - Breast Cancer Testing Growth.....	243
7.3 MDx Colorectal Cancer.....	244
7.3.1 Table Colorectal Cancer Testing – by Country.....	244
7.3.2 Chart - Colorectal Cancer Testing Growth	245
7.4 MDx Cervical Cancer	246
7.4.1 Table Cervical Cancer Testing – by Country	246
7.4.2 Chart - Cervical Cancer Testing Growth.....	247
7.5 MDx Lung Cancer	248
7.5.1 Table Lung Cancer Testing – by Country	248
7.5.2 Chart - Lung Cancer Testing Growth.....	249
7.6 MDx Prostate	250
7.2.1 Table Prostate Testing – by Country	250
7.6.2 Chart - Prostate Testing Growth	251
7.7 MDx Melanoma Cancer	252
7.7.1 Table Melanoma Cancer Testing – by Country	252
7.7.2 Chart - Melanoma Cancer Testing Growth	253
7.8 MDx Blood	254
7.8.1 Table Blood Testing – by Country	254
7.8.2 Chart - Blood Testing Growth	255
7.9 MDx Companion Dx Development	256
7.9.1 Table Companion Dx Development – by Country	256
7.9.2 Chart - Companion Dx Development Growth	257
7.10 MDx Other Cancer	258
7.10.1 Table Other Cancer Testing – by Country	258
7.10.2 Chart - Other Cancer Testing Growth	259
8. Cancer Treatment and Trials	260

8.1 FDA Cancer Drug Approvals by Year 261

8.2 Clinical Trials Started 2010 to 2016..... 262

8.3 Prevalence of Cancer Treatments – 2015 263

Appendices264

I. United States Medicare System: January 2020 Clinical Laboratory Fees Schedule 264

II. FDA Approved Human Genetic Tests 325

III. FDA Approved Microbial Tests 328

III. FDA Approved Pharmacogenomics Tests 337

Table of Tables

Table 1 Lab Spending 2014 to 2024	27
Table 2 Market Players by Type	29
Table 3 Clinical Laboratory Departments and Segments	34
Table 4 Laboratory Management Focus – Different Approaches	35
Table 5 Key Segmentation Variables Going Forward.....	36
Table 6 Five Factors Driving Growth	41
Table 7 Four Factors Limiting Growth	44
Table 8 Key Diagnostic Laboratory Technology Trends	47
Table 9 Next Generation Sequencing Technologies – Speed and Cost	48
Table 10 - Global MDx Cancer Market by Region.....	233
Table 11 Global Market by Cancer Type	236
Table 12 MDx Breast Cancer by Country	242
Table 13 MDx Colorectal Cancer by Country.....	244
Table 14 Cervical Cancer Testing by Country	246
Table 15 Lung Cancer Testing by Country	248
Table 16 Prostate Testing by Country.....	250
Table 17 Melanoma Cancer Testing by Country	252
Table 18 MDx Blood by Country	254
Table 19 MDx Companion Dx Development by Country	256
Table 20 MDx Other Cancer Testing by Country	258
Table 21 2020 Clinical Lab Fee Schedule	264

Table of Figures

Figure 1 Clinical Lab Spending 2014 to 2024	26
Figure 2 Growth in Aging Population	42
Figure 3 Death Rates from Cancer - USA.....	43
Figure 4 Comparing MDx Diagnostic and Traditional Testing	50
Figure 5 Global Market Shares Base Year	234
Figure 6 MDx Market by Cancer - Base vs. Final	237
Figure 7 Cancer Market Base Year	238
Figure 8 Cancer Market Final Year.....	239
Figure 9 MDx Cancer Share by Year	240
Figure 10 MDx Cancer Segment Growth Rates	241
Figure 11 Breast Cancer Testing Growth.....	243
Figure 12 Colorectal Cancer Testing Growth.....	245
Figure 13 Cervical Cancer Testing Growth.....	247
Figure 14 Lung Cancer Testing Growth.....	249
Figure 15 Prostate Testing Growth	251
Figure 16 Melanoma Cancer Testing Growth	253
Figure 17 Blood Testing Growth	255
Figure 18 Companion Dx Development Growth	257
Figure 19 Other Cancer Testing Growth	259
Figure 20 FDA Cancer Drug Approvals by Year.....	261
Figure 21 Clinical Trials for Immunotherapy by Year	262
Figure 22 Pie Chart of Prevalence of Cancer Treatments	263